These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 18568571)

  • 21. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial.
    Stone GW; Midei M; Newman W; Sanz M; Hermiller JB; Williams J; Farhat N; Caputo R; Xenopoulos N; Applegate R; Gordon P; White RM; Sudhir K; Cutlip DE; Petersen JL;
    Circulation; 2009 Feb; 119(5):680-6. PubMed ID: 19171853
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Head-to-head comparison of sirolimus- and paclitaxel-eluting stent in the same diabetic patient with multiple coronary artery lesions: a prospective, randomized, multicenter study.
    Tomai F; Reimers B; De Luca L; Galassi AR; Gaspardone A; Ghini AS; Ferrero V; Favero L; Gioffrè G; Prati F; Tamburino C; Ribichini F
    Diabetes Care; 2008 Jan; 31(1):15-9. PubMed ID: 17909090
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Abciximab administration and clinical outcomes after percutaneous intervention for in-stent restenosis.
    Moustapha A; Assali AR; Sdringola S; Yusuf SW; Vaughn WK; Fish RD; Schroth GW; Krajcer Z; Rosales OR; Smalling RW; Anderson HV
    Catheter Cardiovasc Interv; 2002 Jun; 56(2):184-7. PubMed ID: 12112910
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of drug-eluting and bare-metal stents for primary percutaneous coronary intervention with or without abciximab in ST-segment elevation myocardial infarction: DEBATER: the Eindhoven reperfusion study.
    Wijnbergen I; Helmes H; Tijssen J; Brueren G; Peels K; van Dantzig JM; Van' t Veer M; Koolen JJ; Pijls NH; Michels R
    JACC Cardiovasc Interv; 2012 Mar; 5(3):313-22. PubMed ID: 22440498
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial.
    Stone GW; Ellis SG; Cannon L; Mann JT; Greenberg JD; Spriggs D; O'Shaughnessy CD; DeMaio S; Hall P; Popma JJ; Koglin J; Russell ME;
    JAMA; 2005 Sep; 294(10):1215-23. PubMed ID: 16160130
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A randomized trial comparing phosphorylcholine-coated stenting with balloon angioplasty as well as abciximab with placebo for restenosis reduction in small coronary arteries.
    Hausleiter J; Kastrati A; Mehilli J; Schühlen H; Pache J; Dotzer F; Glatthor C; Siebert S; Dirschinger J; Schömig A;
    J Intern Med; 2004 Nov; 256(5):388-97. PubMed ID: 15485474
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The clinical results of a platelet glycoprotein IIb/IIIa receptor blocker (abciximab: ReoPro)-coated stent in acute myocardial infarction.
    Kim W; Jeong MH; Kim KH; Sohn IS; Hong YJ; Park HW; Kim JH; Ahn YK; Cho JG; Park JC; Cho DL; Kang JC
    J Am Coll Cardiol; 2006 Mar; 47(5):933-8. PubMed ID: 16516074
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Benefits on coronary restenosis from elective paclitaxel-eluting stent implantation in patients aged 75 years and older.
    Sardella G; De Luca L; De Persio G; Colantonio R; Petrolini A; Conti G; Fedele F
    J Cardiovasc Med (Hagerstown); 2007 Jul; 8(7):494-8. PubMed ID: 17568281
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Zotarolimus- and paclitaxel-eluting stents in an all-comer population in China: the RESOLUTE China randomized controlled trial.
    Xu B; Yang Y; Yuan Z; Du Z; Wong SC; Généreux P; Lu S;
    JACC Cardiovasc Interv; 2013 Jul; 6(7):664-70. PubMed ID: 23523240
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sirolimus-eluting versus paclitaxel-eluting stents in diabetic and non-diabetic patients within sirolimus-eluting stent restenosis: results from the ISAR-DESIRE 2 trial.
    Kufner S; Byrne RA; de Waha A; Schulz S; Joner M; Laugwitz KL; Kastrati A;
    Cardiovasc Revasc Med; 2014 Mar; 15(2):69-75. PubMed ID: 24684757
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical impact of abciximab on long-term outcome after complex coronary angioplasty.
    Wijpkema JS; Jessurun GA; Van Boven AJ; Versteeg DI; Hautvast RW; Tio RA
    Catheter Cardiovasc Interv; 2003 Nov; 60(3):339-43. PubMed ID: 14571484
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Abciximab offers greater benefits to insulin-dependent diabetic patients undergoing coronary stent implantation.
    López-Mínguez JR; Nogales JM; González R; Palanco C; Doncel J; Vaello A; Giménez F; Morales A; Alonso R; Merchán A
    Cardiovasc Revasc Med; 2007; 8(3):175-82. PubMed ID: 17765647
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Abciximab therapy and unplanned coronary stent deployment: favorable effects on stent use, clinical outcomes, and bleeding complications. EPILOG Trial Investigators.
    Kereiakes DJ; Lincoff AM; Miller DP; Tcheng JE; Cabot CF; Anderson KM; Weisman HF; Califf RM; Topol EJ
    Circulation; 1998 Mar; 97(9):857-64. PubMed ID: 9521334
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of abciximab on late adverse events in patients with diabetes mellitus undergoing stent implantation.
    Velianou JL; Mathew V; Wilson SH; Barsness GW; Grill DE; Holmes DR
    Am J Cardiol; 2000 Nov; 86(10):1063-8. PubMed ID: 11074200
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial.
    Tcheng JE; Kandzari DE; Grines CL; Cox DA; Effron MB; Garcia E; Griffin JJ; Guagliumi G; Stuckey T; Turco M; Fahy M; Lansky AJ; Mehran R; Stone GW;
    Circulation; 2003 Sep; 108(11):1316-23. PubMed ID: 12939213
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease.
    Stone GW; Ellis SG; Cox DA; Hermiller J; O'Shaughnessy C; Mann JT; Turco M; Caputo R; Bergin P; Greenberg J; Popma JJ; Russell ME;
    N Engl J Med; 2004 Jan; 350(3):221-31. PubMed ID: 14724301
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Two-year clinical outcome after abciximab-coated stent implantation in patients with coronary artery disease.
    Kim SS; Hong YJ; Jeong MH; Kim W; Kim HK; Ko JS; Lee MG; Sim DS; Park KH; Yoon NS; Yoon HJ; Kim KH; Park HW; Kim JH; Ahn Y; Cho JG; Park JC; Song SJ; Cho DL; Kang JC
    Circ J; 2010 Mar; 74(3):442-8. PubMed ID: 20103970
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of coronary culprit lesion calcium in patients undergoing paclitaxel-eluting stent implantation (a TAXUS-IV sub study).
    Moussa I; Ellis SG; Jones M; Kereiakes DJ; McMartin D; Rutherford B; Mehran R; Collins M; Leon MB; Popma JJ; Russell ME; Stone GW
    Am J Cardiol; 2005 Nov; 96(9):1242-7. PubMed ID: 16253590
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of everolimus- and paclitaxel-eluting stents in patients with acute and stable coronary syndromes: pooled results from the SPIRIT (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (A Trial of Everolimus-Eluting Stents and Paclitaxel-Eluting Stents for Coronary Revascularization in Daily Practice) Trials.
    Planer D; Smits PC; Kereiakes DJ; Kedhi E; Fahy M; Xu K; Serruys PW; Stone GW
    JACC Cardiovasc Interv; 2011 Oct; 4(10):1104-15. PubMed ID: 22017936
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Paclitaxel-coated balloon with bare-metal stenting in patients with chronic total occlusions in native coronary arteries.
    Wöhrle J; Werner GS
    Catheter Cardiovasc Interv; 2013 Apr; 81(5):793-9. PubMed ID: 22511572
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.